NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/BMY-Info-Request-Form-1817. There is no cost or obligation to you.
On August 5, 2016, Bristol-Myers revealed that its CheckMate-026 trial exploring the use of Opdivo (nivolumab) as monotherapy failed to meet its primary endpoint of progression-free survival. Following this news, Bristol-Myers stock fell 16% to close at $63.28 per share on August 5, 2016. Then on October 9, 2016, Bristol-Myers revealed the final primary analysis of CheckMate-026, and that the overall Opdivo survival was only 14.4 months compared to chemotherapy's 13.2 months. Following this news, Bristol-Myers stock dropped over 10%, to close at $49.81 per share on October 10, 2016.
To learn more about the investigation of Bristol-Myers contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/BMY-Info-Request-Form-1817.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.